Evidence map›Paper›PMID 40804012›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Weak and Tunable Adhesion-Clutch Drives Rapid Cell Migration and Glioblastoma Invasion.

Kentarou Baba, Ami Fukushi-Kumagai, Megumi Morisaki, Ryosuke Takeuchi, Zhize Xiao, Yoshikazu Nagashima, Mizuki Sakai, Yasuna Higashiguchi, Hiroko Katsuno-Kambe, Asako Katsuma and 6 more

Abstract readVideo-Audio Media
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The novel [RSC advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Weak and Tunable Adhesion-Clutch Drives Rapid Cell Migration and Glioblastoma Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kentarou BabaDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.ORCID https://orcid.org/0000-0002-3002-3129
Ami Fukushi-KumagaiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Megumi MorisakiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Ryosuke TakeuchiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Zhize XiaoDepartment of Neuro-Oncology, Institute of Brain Science, Nagoya City University, Nagoya 467-8601, Japan.
Yoshikazu NagashimaDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Mizuki SakaiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Yasuna HigashiguchiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Hiroko Katsuno-KambeDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Asako KatsumaDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Yoshihiro UedaDepartment of Molecular Genetics, Institute of Biomedical Science, Kansai Medical University, Hirakata 573-1010, Japan.
Yuji KamiokaDepartment of Molecular Genetics, Institute of Biomedical Science, Kansai Medical University, Hirakata 573-1010, Japan.
Daisuke KawauchiDepartment of Neuro-Oncology, Institute of Brain Science, Nagoya City University, Nagoya 467-8601, Japan.
Tatsuo KinashiDepartment of Molecular Genetics, Institute of Biomedical Science, Kansai Medical University, Hirakata 573-1010, Japan.
Yonehiro KanemuraDivision of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Naoyuki InagakiDivision of Biological Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.ORCID https://orcid.org/0000-0002-2664-9196

Funding

Japan Agency for Medical Research and Development JP17gm0810011Japan Society for the Promotion of Science JP25K18854JSPS Grants-in-Aid for Early-Career Scientists 25K18854JSPS Grants-in-Aid for Early-Career Scientists JP19K16127JSPS KAKENHI 25K02272JSPS KAKENHI JP19H03223
6 · The paper itself

Abstract

To move forward, cells must exert backward forces against their surrounding environment. Recent studies have highlighted the importance of integrin-independent forces for cell migration; however, the molecular machinery that exerts forces remains unclear. This study shows that the clutch-linker molecule shootin1 and the cell adhesion molecule L1 transmit the backward force of treadmilling actin filaments to the environment, enabling rapid dendritic cell migration. Notably, shootin1 and L1 transmit weak traction forces, up to ∼100 times weaker than integrin-based forces, by constituting an integrin-independent slippery adhesion-clutch. This adhesion-clutch is tunable in response to the chemoattractant CCL19 and the adhesive ligand laminin, thereby enabling chemotaxis and haptokinesis. Furthermore, aberrant activity of this adhesion-clutch enhances glioblastoma cell invasion. The results show that the weak adhesion-clutch is well-suited for rapid cell migration, without forming strong adhesions that impede cell motility, and provides a potential target for inhibiting abnormal tumor invasion.

Indexed as

Brain NeoplasmsCell MovementGlioblastomaNerve Tissue ProteinsNeural Cell Adhesion Molecule L1AnimalsCell Line, TumorChemokine CCL19FemaleHEK293 CellsHumansLamininMaleMiceMice, KnockoutNeoplasm InvasivenessChemokine CCL19LamininNerve Tissue ProteinsNeural Cell Adhesion Molecule L1shootin 1 protein, mouseadhesioncancer invasionchemotaxisclutchleukocyte

Identifiers

PMID40804012
PMCPMC12533206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.